The promising results of a phase 1 clinical trial for the immunotherapy approach also showed that seven other women had no measurable disease at the end of the trial, the researchers added.
Their results are scheduled to be presented Saturday at the American Association for Cancer Research's annual meeting in Washington, D.C.
Ovarian cancer is fairly rare -- an estimated 1.38 percent of females born today will be diagnosed with the condition -- but it's an especially deadly form of cancer because it is usually diagnosed in an advanced stage.
The new treatment uses a personalized vaccine to try to teach the body's immune system how to fight off tumors.
After recently gaining recognition as the first professional Santa Claus with Down syndrome in the US,...
As a new NFL season begins this Wednesday, the danger of America’s most-watched sport has never...
